An evaluation of secukinumab for the treatment of moderate-to-severe hidradenitis suppurativa.

As response to anti-TNFas is lost over time, secukinumab has provided an alternative HS treatment option in clinical practice. Overall, secukinumab has shown good efficacy and a favorable side effect profile in HS clinical trials but may be avoided in patients with inflammatory bowel disease. Long term and real-life data on the use of secukinumab are essential for improving decision-making in HS therapy.